Korean J Ophthalmol.  2013 Jun;27(3):167-171. 10.3341/kjo.2013.27.3.167.

The Effect of Topical Cyclosporine 0.05% on Dry Eye after Cataract Surgery

• Chung YW
• Oh TH
• Chung SK

• KMID: 1798053
• DOI: http://doi.org/10.3341/kjo.2013.27.3.167

Abstract

PURPOSE
To evaluate the effectiveness of cyclosporine 0.05% for dry eye after cataract surgery.
METHODS
Thirty-two newly diagnosed patients with dry eye syndrome 1 week after cataract surgery received a twice-daily treatment of cyclosporine 0.05% for one eye and normal saline 0.9% for the other. Disease severity was measured at 2 weeks, 1 month, 2 months, and 3 months by Schirmer test I (ST-I), tear film break-up time (tBUT), corneal temperature and dry eye symptom questionnaire (Ocular Surface Disease Index).
RESULTS
Both groups increased in ST-I and tBUT over time. ST-I in the cyclosporine 0.05% group showed a significant increase at 3 months and tBUT in the cyclosporine 0.05% group showed an increase at 2 and 3 months. The dry eye symptom score was significantly reduced in the cyclosporine 0.05% group.
CONCLUSIONS
Cyclosporine 0.05% can also be an effective treatment for dry eye after cataract surgery.

Keyword

Cataract surgery; Cyclosporine; Dry eye syndromes

MeSH Terms

Aged
Aged, 80 and over
*Cataract Extraction
Cyclosporine/*administration & dosage
Dry Eye Syndromes/*drug therapy
Female
Humans
Immunosuppressive Agents/administration & dosage
Male
Middle Aged
Ophthalmic Solutions/*administration & dosage
Postoperative Complications/*drug therapy
Treatment Outcome
Immunosuppressive Agents
Ophthalmic Solutions
Cyclosporine

Figure

• 

  Fig. 1 Changes of Schirmer test I score over time in the cyclosporine 0.05% and normal saline 0.9% groups.

• 

  Fig. 2 Changes of tear film break-up time in the cyclosporine 0.05% and normal saline 0.9% groups over time.

• 

  Fig. 3 Changes of corneal temperature in the two groups.

• 

  Fig. 4 Changes of symptom severity score in the two groups. (A) Intensity score, (B) frequency score, and (C) aggravation score.

Reference

1. Kohlhaas M. Corneal sensation after cataract and refractive surgery. J Cataract Refract Surg. 1998. 24:1399–1409.

2. Li XM, Hu L, Hu J, Wang W. Investigation of dry eye disease and analysis of the pathogenic factors in patients after cataract surgery. Cornea. 2007. 26:9 Suppl 1. S16–S20.

3. Cho YK, Kim MS. Dry eye after cataract surgery and associated intraoperative risk factors. Korean J Ophthalmol. 2009. 23:65–73.

4. Wilson SE, Perry HD. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Ophthalmology. 2007. 114:76–79.

5. Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol. 2009. 54:321–338.

6. Thomas PB, Samant DM, Zhu Z, et al. Long-term topical cyclosporine treatment improves tear production and reduces keratoconjunctivitis in rabbits with induced autoimmune dacryoadenitis. J Ocul Pharmacol Ther. 2009. 25:285–292.

7. Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol. 2004. 137:337–342.

8. Stern ME, Gao J, Siemasko KF, et al. The role of the lacrimal functional unit in the pathophysiology of dry eye. Exp Eye Res. 2004. 78:409–416.

9. Donnenfeld ED, Solomon K, Perry HD, et al. The effect of hinge position on corneal sensation and dry eye after LASIK. Ophthalmology. 2003. 110:1023–1029.

10. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007). Ocul Surf. 2007. 5:75–92.

11. Walker TD. Benzalkonium toxicity. Clin Experiment Ophthalmol. 2004. 32:657.

12. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000. 107:631–639.

13. Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 2000. 47:119–125.

14. Stern ME, Gao J, Schwalb TA, et al. Conjunctival T-cell subpopulations in Sjogren's and non-Sjogren's patients with dry eye. Invest Ophthalmol Vis Sci. 2002. 43:2609–2614.

15. Strong B, Farley W, Stern ME, Pflugfelder SC. Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca. Cornea. 2005. 24:80–85.

16. Sahli E, Hoşal BM, Zilelioglu G, et al. The effect of topical cyclosporine A on clinical findings and cytological grade of the disease in patients with dry eye. Cornea. 2010. 29:1412–1416.

17. Baiza-Durán L, Medrano-Palafox J, Hernandez-Quintela E, et al. A comparative clinical trial of the efficacy of two different aqueous solutions of cyclosporine for the treatment of moderate-to-severe dry eye syndrome. Br J Ophthalmol. 2010. 94:1312–1315.

18. Tananuvat N, Daniell M, Sullivan LJ, et al. Controlled study of the use of autologous serum in dry eye patients. Cornea. 2001. 20:802–806.

19. Mengher LS, Pandher KS, Bron AJ, Davey CC. Effect of sodium hyaluronate (0.1%) on break-up time (NIBUT) in patients with dry eyes. Br J Ophthalmol. 1986. 70:442–447.

20. Sheppard JD, Scoper SV, Samudre S. Topical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye disease. J Ocul Pharmacol Ther. 2011. 27:23–27.